Pharma BD Deal Intelligence
Merck KGaA paid $7.2B for Millipore—the first step in a $24B life science tools strategy completed with the Sigma-Aldrich acquisition five years later. The deal brought filtration, cell culture, and bioprocessing capabilities that serve as essential infrastructure for biopharmaceutical manufacturing.
Merck KGaA / Millipore: Achieved Stated Rationale (Score: 79/100)
Full analysis, sources & comparables →Merck KGaA acquired Millipore for $7.2B (EUR 5.3B) for life science business.
Merck KGaA and Millipore announce a definitive agreement for Merck KGaA to acquire all outstanding shares at $107 per share in cash, for a total transaction…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Merck KGaA acquired Millipore for $7.2B (EUR 5.3B) for life science business.
Merck KGaA / Millipore: Achieved Stated Rationale (Score: 79/100)
Assessment window: 15yr post-close.
Merck KGaA closes acquisition/merger of Millipore Corporation for $7.2B, establishing strategic position and initiating integration.
Strategic Fit: 88/100 | Financial Return: 82/100 | Pipeline Outcome: 65/100 | Integration: 78/100 | Deal Difficulty: 50/100. Achieved Stated Rationale overall outcome.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck KGaA / Millipore Corporation (this deal) | 2010 | $7.2B | 88 |
| Merck KGaA / Sigma-Aldrich Corporation | 2014 | $17.0B | 80 |
| Merck KGaA / Versum Materials | 2019 | $5.8B | 80 |
| Merck KGaA / Serono SA | 2006 | $13.2B | 74 |
| Merck KGaA / SpringWorks Therapeutics | 2025 | $3.4B | 72 |
| Merck KGaA / Threshold Pharmaceuticals, Inc. | 2012 | $550M | — |
| Merck KGaA / Debiopharm | 2021 | $1.1B | — |
← Browse all deals · How we score deals
More: 2010 deals · Merck KGaA deals